Monte Rosa Therapeutics (GLUE) Stock Overview
A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GLUE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Monte Rosa Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.81 |
| 52 Week High | US$25.77 |
| 52 Week Low | US$3.90 |
| Beta | 1.62 |
| 1 Month Change | -4.95% |
| 3 Month Change | 3.98% |
| 1 Year Change | 371.43% |
| 3 Year Change | 188.50% |
| 5 Year Change | n/a |
| Change since IPO | -11.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| GLUE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.0% | 3.1% | 1.2% |
| 1Y | 371.4% | 34.6% | 28.7% |
Return vs Industry: GLUE exceeded the US Biotechs industry which returned 34.6% over the past year.
Return vs Market: GLUE exceeded the US Market which returned 28.7% over the past year.
Price Volatility
| GLUE volatility | |
|---|---|
| GLUE Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLUE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GLUE's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 187 | Markus Warmuth | www.monterosatx.com |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast.
Monte Rosa Therapeutics, Inc. Fundamentals Summary
| GLUE fundamental statistics | |
|---|---|
| Market cap | US$1.59b |
| Earnings (TTM) | -US$130.01m |
| Revenue (TTM) | US$42.95m |
Is GLUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLUE income statement (TTM) | |
|---|---|
| Revenue | US$42.95m |
| Cost of Revenue | US$145.41m |
| Gross Profit | -US$102.46m |
| Other Expenses | US$27.55m |
| Earnings | -US$130.01m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.54 |
| Gross Margin | -238.54% |
| Net Profit Margin | -302.69% |
| Debt/Equity Ratio | 0% |
How did GLUE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/26 07:25 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Monte Rosa Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Michael Schmidt | Guggenheim Securities, LLC |
| Dingding Shi | Jefferies LLC |